Limitations, agreements, and source contact

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma · Source last updated 2018-11-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

limitations And Caveats

description

Analysis available and entered in the results section for Phase I participants. Cannot submit results on Phase II because analysis was incomplete when PI left MSK.

point Of Contact

email

portlocc@mskcc.org

organization

Memorial Sloan Kettering Cancer Center

phone

212-639-8109

title

Dr. Carol Portlock

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice